Mechanisms for cardiorenal protection of sglt-2 inhibitors
Ημερομηνία
2021Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Despite optimal treatment of diabetic kidney disease (DKD) with adequate blood pressure control and agents blocking the renin-angiotensin-system (RAS), the residual cardiorenal risk of these patients remains substantially high. There is, therefore, an unmet need for additional therapies effective to retard the progression of DKD and improve cardiovascular outcomes in this high-risk population. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors represent a novel drug class that received regulatory approval for improving glycemic control in patients with type 2 diabetes and preserved kidney function. Large outcome trials designed to test their cardiovascular safety profile showed an unexpected improvement in cardiovascular outcomes and also suggested a slower progression of DKD with SGLT-2 inhibition. The Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE), a trial that was designed to specifically investigate the renoprotective properties of SGLT-2 inhibitors in patients with overt DKD already receiving guideline-based therapy with a RAS-blocker, was prematurely terminated due to an impressive benefit of canagliflozin on kidney and cardiovascular outcomes. These impressive results refine the role and the indication of SGLT-2 inhibitors as a cardio-and renoprotective strategy in patients with DKD. In this article, we provide an overview of the available clinical-trial evidence and explore the mechanisms mediating the cardiorenal protection afforded by SGLT-2 inhibitors. We conclude with perspectives for a potential beneficial effect of this novel drug class in patients with non-diabetic kidney disease. © 2021 Bentham Science Publishers.
Collections
Related items
Showing items related by title, author, creator and subject.
-
SGLT-2 inhibitors in diabetic kidney disease: What lies behind their renoprotective properties?
Georgianos P.I., Divani M., Eleftheriadis T., Mertens P.R., Liakopoulos V. (2019)Background: Despite optimal management of diabetic kidney disease (DKD) with intensive glycemic control and administration of agents blocking the renin-angiotensinaldosterone-system, the residual risk for nephropathy ... -
Meta-analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on the Risk for New-Onset Obstructive Sleep Apnea in Patients With Type 2 Diabetes Mellitus Regardless of Cardiovascular Disease at Baseline
Patoulias D., Dimosiari A., Michailidis T., Roditis P., Lampropoulos S. (2022)[No abstract available] -
Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass
Ferreira A., Emara A.F.A., Herzig D., Melmer A., Vogt A.P., Nakas C.T., Facchinetti A., Dalla Man C., Bally L. (2022)Introduction Postprandial hypoglycaemia after gastric bypass surgery (also known as postbariatric hypoglycaemia or PBH) is an increasingly encountered clinical problem. PBH is characterised by meal-induced rapid spikes and ...